Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445944 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2PKMALDH1A1CTSSHTT | |
| SCHEMBL5839241 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2PKMALDH1A1CTSSHTT | |
| SCHEMBL13645754 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMALDH1A1ACACBDPP4 | |
| SCHEMBL28448280 | 0.76 | HTT (0.39) | SMN1; SMN2PKMALDH1A1ACACBCTSS | |
| SCHEMBL15413810 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2PKMALDH1A1HTTMAPT | |
| SCHEMBL6712903 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2PKMALDH1A1CTSS | |
| SCHEMBL132349 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1203937 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL193513 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7105559 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | SMN1; SMN2 1200/4885PKM 2587/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.